Tower Research Capital (TRC)’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $390K | Sell |
77,170
-23,835
| -24% | -$121K | 0.01% | 1188 |
|
|
2025
Q1 | $534K | Buy |
101,005
+95,578
| +1,761% | +$506K | 0.02% | 799 |
|
|
2024
Q4 | $36.7K | Buy |
5,427
+616
| +13% | +$4.16K | ﹤0.01% | 2755 |
|
|
2024
Q3 | $31.7K | Sell |
4,811
-29,252
| -86% | -$193K | ﹤0.01% | 2972 |
|
|
2024
Q2 | $255K | Buy |
34,063
+19,585
| +135% | +$147K | ﹤0.01% | 1887 |
|
|
2024
Q1 | $144K | Buy |
14,478
+874
| +6% | +$8.71K | ﹤0.01% | 1621 |
|
|
2023
Q4 | $134K | Buy |
13,604
+5,314
| +64% | +$52.4K | ﹤0.01% | 2411 |
|
|
2023
Q3 | $63.4K | Sell |
8,290
-10,228
| -55% | -$78.2K | ﹤0.01% | 2351 |
|
|
2023
Q2 | $138K | Buy |
18,518
+3,574
| +24% | +$26.7K | ﹤0.01% | 1802 |
|
|
2023
Q1 | $100K | Buy |
14,944
+12,645
| +550% | +$84.6K | ﹤0.01% | 1874 |
|
|
2022
Q4 | $18K | Sell |
2,299
-13,112
| -85% | -$103K | ﹤0.01% | 3232 |
|
|
2022
Q3 | $164K | Buy |
15,411
+10,649
| +224% | +$113K | ﹤0.01% | 2117 |
|
|
2022
Q2 | $39K | Buy |
4,762
+1,824
| +62% | +$14.9K | ﹤0.01% | 3127 |
|
|
2022
Q1 | $21K | Sell |
2,938
-1,171
| -28% | -$8.37K | ﹤0.01% | 3494 |
|
|
2021
Q4 | $70K | Buy |
4,109
+3,528
| +607% | +$60.1K | ﹤0.01% | 2491 |
|
|
2021
Q3 | $14K | Sell |
581
-1,931
| -77% | -$46.5K | ﹤0.01% | 4040 |
|
|
2021
Q2 | $91K | Buy |
+2,512
| New | +$91K | ﹤0.01% | 2506 |
|